Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months.
This survival data along with radiographic improvements are indicative of positive treatment effects, which highlights the potential of IN8bio’s genetically modified, chemotherapy-resistant gamma-delta T cells as a potential first-in-class therapy for patients with newly diagnosed glioblastoma. Glioblastoma multiforme is the most aggressive type of cancer originating in the brain.
The clinical trial was led by Burt Nabors, M.D., in collaboration with IN8bio. Nabors is a professor of neurology at UAB, division director of Neuro-Oncology and a senior scientist in the O’Neal Comprehensive Cancer Center at UAB. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue…
Read the full article here.